November-December 2014: Volume 15 Number 11/12

ARV supply issues cause treatment interruptions in a UK clinic

12th Glasgow Congress on HIV Therapy, 2-6 November 2014, Glasgow

Savings to the NHS predicted from switching to generic antiretrovirals

Lower dose efavirenz effective in two studies

Should tenofovir dose be 200 – 250 mg when used with protease inhibitors?

3TC inferior to FTC in Dutch cohort but interchangeable in other studies

Suicide not associated with efavirenz use in the D:A:D cohort study

Gender differences in use of cardiovascular disease-related interventions: D:A:D study

Efavirenz decreases exposure to hormonal contraceptive implant

Increased risk of ART-related hepatotoxicity in HIV positive pregnant women

Darunavir pharmacokinetics in pregnancy and postpartum

BHIVA Autumn Conference, 9-10 October 2014, London

Good management of HIV positive pregnant women in UK – with some room for improvement

Southern African Clinicians Society Conference, 24-27 September 2014, Cape Town, South Africa

Efavirenz-associated gynaecomastia reported to the national HIV and TB healthcare workers hotline in South Africa

Infants start ART too late but improvement over time in Southern Africa

Treatment outcomes in HIV positive and negative people with drug resistant TB in Khayelitsha, Cape Town

Pregnancy a risk factor for poor antiretroviral treatment outcomes in South African adolescents

Poppers-related maculopathy linked to permanent and serious vision loss

Equivalent efficacy with lower dose darunavir

US activists called on Gilead to set a per-treatment price for sofosbuvir/ledipasvir

UK PROUD study to provide PrEP to all participants earlier than expected: planned follow-up to continue to two years

IPERGAY PrEP study shows early efficacy in protecting gay men from HIV: all participants to switch to active drug

Three papers on macrophages and HIV infection

HIV in the UK 2014: Public Health England report on incidence and care


Online article

November/December 2014: Volume 15 Number 11/12

UK PROUD study to provide PrEP earlier than expected: planned follow-up to continue to two years

September/October 2014: Volume 15 Number 9/10

54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 5-9 
September 2014, Washington, DC

Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep

HIV persists in lung macrophages of people on suppressive ART

Only 10% of veterans with HCV or HCV/HIV in the US treated for HCV

20th International AIDS Conference, 20-25 July 2014, Melbourne

Update on baseline STIs in UK oral PrEP study (PROUD)

High prevalence of COPD at baseline in START study sub-study

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Rosuvastatin may be partially effective in moderating residual immune activation on ART

Reasons for loss to follow up in the Malawi Option B+ programme

Single-pill dolutegravir/abacavir/3TC (Triumeq) approved in EU and US

Cobicistat and elvitegravir approved in the US as single pills

Positive opinion to approve of darunavir/cobicistat in Europe

UK updates PEP guidelines (2014): raltegravir replaces PIs and no indication if positive partner has an undetectable viral load

BHIVA pregnancy guidelines: 2014 interim update

US HIV guidelines for management of chronic kidney disease (IDSA, 2014)

Raltegravir pharmacokinetics in pregnancy and neonates

Efavirenz pharmacokinetics among pregnant women with and without tuberculosis coinfection

Immunotherapy for PML: two case reports using IL-7 and experimental recombinant JCV VP1 protein therapeutic vaccination

Kidney signal trouble worsens over 5 years in Japanese on tenofovir

Case report: Stem cell transplantation from CCR5 delta-32 homozygous donor selects for X4-tropic HIV

HIV reinfection has limited impact on disease progression

Stemming the flow from HIV reservoirs with neutralising antibodies

Daclatasvir approved in EU for HCV genotypes 1-4

CHMP gives positive opinion to approve coformulated sofosbuvir/ledipasvir

European activists protest at meeting of European Health Ministers for access to new HCV drugs

DSMB open report strongly supports importance of START study

September/October 2014: Volume 15 Number 9/10 – PDF

July/August 2014: Volume 15 Number 7/8

20th International AIDS Conference, 20-25 July 2014, Melbourne

The loss of friends and colleagues from flight MH 17

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

Pill A, Pill B: simplified second-line treatment for low-income countries

Post navigation